Wall Street analyst estimates for Oaktree Acquisition Corp. II (OACC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-12 | $0.07 |
Valuation Ratios
| P/E Ratio | 38.12 |
| Price / Book | 1.05 |
| EV / EBITDA | -220.35 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Research & Development | 0 | 0 |
| Selling, General & Admin | $704 | $1.2M |
| Operating Expenses | $704 | $1.2M |
| Operating Income | -$703 | -$1.2M |
| EBITDA | -$351806 | -$1.2M |
| Interest Expense | 0 | 0 |
| Pre-tax Income | $2663 | $7.3M |
| Income Tax | 0 | 0 |
| Net Income | $2663 | $7.3M |
| EPS | $0.05 | $0.30 |
| EPS (Diluted) | $0.05 | $0.30 |
| Shares Outstanding (Diluted) | $24.6M | $19.2M |
Price
| Price | $10.78 |
| Market Cap | $265M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AACB · CGCT · COPL · FACT · MBAV · MLAC · PMTR
Explore sector: Financial Services · Shell Companies
More sections of OACC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks